Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP731214.RAb7l-D1-mAjrTP2c7RS5nlw1V1YDDEn6m5Q32DwGKQ9M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP731214.RAb7l-D1-mAjrTP2c7RS5nlw1V1YDDEn6m5Q32DwGKQ9M130_assertion type Assertion NP731214.RAb7l-D1-mAjrTP2c7RS5nlw1V1YDDEn6m5Q32DwGKQ9M130_head.
- NP731214.RAb7l-D1-mAjrTP2c7RS5nlw1V1YDDEn6m5Q32DwGKQ9M130_assertion description "[Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha) (MR1) and its binding site, the epidermal growth factor receptor (EGFR) (MR2), are efficacious against the UACC 897 breast, PC-3 and LNCaP prostate, and T98G glioblastoma tumor lines in both in vitro and in vivo studies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP731214.RAb7l-D1-mAjrTP2c7RS5nlw1V1YDDEn6m5Q32DwGKQ9M130_provenance.
- NP731214.RAb7l-D1-mAjrTP2c7RS5nlw1V1YDDEn6m5Q32DwGKQ9M130_assertion evidence source_evidence_literature NP731214.RAb7l-D1-mAjrTP2c7RS5nlw1V1YDDEn6m5Q32DwGKQ9M130_provenance.
- NP731214.RAb7l-D1-mAjrTP2c7RS5nlw1V1YDDEn6m5Q32DwGKQ9M130_assertion SIO_000772 17972023 NP731214.RAb7l-D1-mAjrTP2c7RS5nlw1V1YDDEn6m5Q32DwGKQ9M130_provenance.
- NP731214.RAb7l-D1-mAjrTP2c7RS5nlw1V1YDDEn6m5Q32DwGKQ9M130_assertion wasDerivedFrom befree-20150227 NP731214.RAb7l-D1-mAjrTP2c7RS5nlw1V1YDDEn6m5Q32DwGKQ9M130_provenance.
- NP731214.RAb7l-D1-mAjrTP2c7RS5nlw1V1YDDEn6m5Q32DwGKQ9M130_assertion wasGeneratedBy ECO_0000203 NP731214.RAb7l-D1-mAjrTP2c7RS5nlw1V1YDDEn6m5Q32DwGKQ9M130_provenance.